[{"address1": "4551 Kennedy Commerce Drive", "city": "Houston", "state": "TX", "zip": "77032", "country": "United States", "phone": "713 400 6400", "website": "https://www.markertherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.", "fullTimeEmployees": 67, "companyOfficers": [{"maxAge": 1, "name": "Ms. Elizabeth  Donnelly", "title": "Director of Administration", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edmund  Cheung", "title": "Vice President of Human Resources", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nadia  Agopyan Ph.D.", "title": "Senior Vice President of Regulatory Affairs", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Monic  Stuart M.D.", "title": "Chief Medical Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gerald  Garrett", "title": "Senior Vice President of Clinical Operations", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael J. Loiacono", "age": 57, "title": "Treasurer & Secretary", "yearBorn": 1966, "fiscalYear": 2018, "totalPay": 287981, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert Z. Florkiewicz Sr.", "title": "Senior Director of Molecular Biology & Virology", "fiscalYear": 2018, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1546214400, "maxAge": 86400, "priceHint": 4, "previousClose": 4.63, "open": 4.52, "dayLow": 4.52, "dayHigh": 4.8, "regularMarketPreviousClose": 4.63, "regularMarketOpen": 4.52, "regularMarketDayLow": 4.52, "regularMarketDayHigh": 4.8, "beta": 1.485, "forwardPE": -1.3647058, "volume": 23492, "regularMarketVolume": 23492, "averageVolume": 24736, "averageVolume10days": 19820, "averageDailyVolume10Day": 19820, "bid": 3.32, "ask": 5.93, "bidSize": 200, "askSize": 200, "marketCap": 41245052, "fiftyTwoWeekLow": 0.67, "fiftyTwoWeekHigh": 9.68, "priceToSalesTrailing12Months": 4.844526, "fiftyDayAverage": 4.261, "twoHundredDayAverage": 4.3242, "currency": "USD", "enterpriseValue": 23771154, "profitMargins": -1.0912, "floatShares": 6733077, "sharesOutstanding": 8889020, "sharesShort": 160877, "sharesShortPriorMonth": 175941, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.018099999, "heldPercentInsiders": 0.12186, "heldPercentInstitutions": 0.22986001, "shortRatio": 9.8, "shortPercentOfFloat": 0.0252, "impliedSharesOutstanding": 8889020, "bookValue": 1.88, "priceToBook": 2.468085, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -24503900, "trailingEps": -2.86, "forwardEps": -3.4, "lastSplitFactor": "1:10", "lastSplitDate": 1674777600, "enterpriseToRevenue": 2.792, "enterpriseToEbitda": -1.084, "52WeekChange": 4.5903616, "SandP52WeekChange": 0.31995547, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "MRKR", "underlyingSymbol": "MRKR", "shortName": "Marker Therapeutics, Inc.", "longName": "Marker Therapeutics, Inc.", "firstTradeDateEpochUtc": 1026826200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f52316f7-d523-378a-bebe-a89c89d1c289", "messageBoardId": "finmb_1725474", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.64, "targetHighPrice": 12.5, "targetLowPrice": 12.5, "targetMeanPrice": 12.5, "targetMedianPrice": 12.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 17473900, "totalCashPerShare": 1.966, "ebitda": -21932096, "quickRatio": 6.317, "currentRatio": 7.011, "totalRevenue": 8513744, "revenuePerShare": 0.981, "returnOnAssets": -0.51230997, "returnOnEquity": -1.24674, "freeCashflow": -19333748, "operatingCashflow": -20377800, "revenueGrowth": -0.742, "grossMargins": -1.8369, "ebitdaMargins": -2.57608, "operatingMargins": -12.42225, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-03-22"}]